Please login to the form below

Not currently logged in
Email:
Password:

Solymbic

This page shows the latest Solymbic news and features for those working in and with pharma, biotech and healthcare.

Amgen wins European approval for Humira biosimilar Amgevita

Amgen wins European approval for Humira biosimilar Amgevita

Meanwhile, in Europe Amgen’s new product has a duplicate marketing authorisation under the brand name Solymbic.

Latest news

  • Merck confirms sale of biosimilar division Merck confirms sale of biosimilar division

    In January, the EMA's Committee for Medicinal Products for Human Use (CHMP) backed approval of the Humira biosimilar under two brand names - Amgevita and Solymbic – with approval expected in the

  • Amgen's Humira biosimilars backed for EU approval Amgen's Humira biosimilars backed for EU approval

    Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster. AbbVie's Humira (adalimumab) looks set to be on the defensive in Europe as well as the US this year, after the ... Amgen's biosimilars - Amgevita (ABP 501) and Solymbic - were recommended

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics